RPS6KA1 (Ab-348) Antibody

What is RPS6KA1 (Ab-348) Antibody and what epitope does it recognize?

RPS6KA1 (Ab-348) Antibody is a rabbit polyclonal antibody that specifically recognizes the peptide sequence around amino acids 346-350 (S-R-T-P-R) of human p90RSK/RSK1/RPS6KA1 . This region contains threonine 348, a phosphorylation site that plays a crucial role in p90RSK activation. The antibody detects endogenous levels of total p90RSK protein and is valuable for studying RSK1 function and regulation in various cellular contexts .

What applications is the RPS6KA1 (Ab-348) Antibody validated for?

The RPS6KA1 (Ab-348) Antibody has been validated for multiple research applications:

For Western blot applications, the antibody typically detects a band at 83-90 kDa, corresponding to the molecular weight of RPS6KA1 . Validation data demonstrates successful detection in various cell lines including HeLa and 3T3 cells .

What species reactivity has been confirmed for RPS6KA1 (Ab-348) Antibody?

The RPS6KA1 (Ab-348) Antibody has been experimentally confirmed to react with samples from the following species:

• Human

• Mouse

• Rat

This cross-reactivity makes it a versatile tool for comparative studies across different mammalian models . When working with other species, preliminary validation is recommended as cross-reactivity may vary.

How should I optimize Western blot conditions when using RPS6KA1 (Ab-348) Antibody?

For optimal Western blot results with RPS6KA1 (Ab-348) Antibody:

• Sample preparation:

  • Extract total protein from cells using a lysis buffer containing phosphatase inhibitors to preserve phosphorylation states

  • Load 20-40 μg of total protein per lane

• Running conditions:

  • Use 8-10% SDS-PAGE gels for optimal separation of the 83-90 kDa RPS6KA1 protein

• Transfer and blocking:

  • Transfer to PVDF membranes at 100V for 90 minutes or 30V overnight

  • Block with 5% BSA in TBST (preferred over milk for phospho-specific detection)

• Antibody incubation:

  • Primary antibody: Use at 1:500-1:1000 dilution in 5% BSA/TBST

  • Incubate overnight at 4°C for highest sensitivity

  • Secondary antibody: Anti-rabbit HRP at 1:5000-1:10000 for 1 hour at room temperature

• Detection:

  • Use ECL substrate appropriate for your expected signal strength

  • Expected band size: 83-90 kDa, with possible additional band at 73 kDa

These conditions should be optimized based on your specific cell type and experimental conditions. K-562 cells have been confirmed as a positive control .

What are the recommended protocols for immunofluorescence using RPS6KA1 (Ab-348) Antibody?

For optimal immunofluorescence results:

• Cell preparation:

  • Grow cells on coverslips to 70-80% confluence

  • Fix with 4% paraformaldehyde (10 minutes) or methanol (5 minutes at -20°C)

  • Methanol fixation is preferred as demonstrated in HeLa cell validation studies

• Permeabilization and blocking:

  • Permeabilize with 0.1% Triton X-100 in PBS for 5 minutes (if using paraformaldehyde)

  • Block with 1-3% BSA in PBS for 30 minutes

• Antibody incubation:

  • Primary antibody: Dilute 1:100-1:200 in blocking solution

  • Incubate for 1-2 hours at room temperature or overnight at 4°C

  • Secondary antibody: Anti-rabbit fluorescent conjugate at 1:500, 1 hour at room temperature

• Counterstaining and mounting:

  • DAPI (1:1000) for nuclear counterstaining

  • Mount with anti-fade mounting medium

Validation data shows clear cytoplasmic and nuclear staining in HeLa cells, consistent with the known subcellular localization of RPS6KA1 .

How can I validate the specificity of the RPS6KA1 (Ab-348) Antibody in my experimental system?

To validate antibody specificity:

• Positive and negative controls:

  • Positive controls: K-562 or HeLa cells, which express detectable levels of RPS6KA1

  • Negative controls: RPS6KA1 knockdown cells (siRNA or CRISPR)

• Peptide competition assay:

  • Pre-incubate antibody with excess immunogenic peptide (S-R-T-P-R sequence)

  • Run parallel Western blots with blocked and unblocked antibody

  • Specific bands should disappear in the peptide-blocked sample

• Molecular weight verification:

  • Confirm that detected bands match the expected molecular weight (83-90 kDa)

  • Be aware that phosphorylated forms may show slight mobility shifts

• Multiple detection methods:

  • Compare results across different applications (WB, IF, ELISA)

  • Consistent results across methods strengthen confidence in specificity

• Cross-reference with other validated RPS6KA1 antibodies:

  • Compare staining patterns with other antibodies targeting different epitopes of RPS6KA1

What are the common challenges in interpreting RPS6KA1 (Ab-348) Antibody Western blot data?

Several factors can complicate RPS6KA1 (Ab-348) Antibody data interpretation:

• Multiple bands: RPS6KA1 can appear as multiple bands between 73-90 kDa , which may represent:

  • Alternative splice variants (documented isoforms)

  • Different phosphorylation states

  • Proteolytic cleavage products

• Phosphorylation-dependent mobility shifts:

  • Phosphorylated RPS6KA1 may migrate differently than unphosphorylated forms

  • Treatment with phosphatase inhibitors before lysis can preserve physiological phosphorylation

• Cross-reactivity with other RSK family members:

  • The antibody may detect other RSK family proteins (RSK2, RSK3, RSK4) due to sequence similarity

  • Verification with knockout/knockdown controls is recommended

• Cell type-specific expression levels:

  • Expression and phosphorylation status varies across cell types

  • K-562 cells show high expression and can serve as positive controls

• Stimulation-dependent changes:

  • Growth factor or stress stimulation can dramatically alter RPS6KA1 phosphorylation and expression

  • Include appropriate stimulated and unstimulated controls

To address these challenges, always include molecular weight markers and appropriate controls, and consider using complementary detection methods.

How can I differentiate between true RPS6KA1 signal and non-specific binding?

To differentiate specific from non-specific signals:

• Use validated positive controls:

  • HeLa or K-562 cell lysates show consistent RPS6KA1 expression patterns

• Include genetic controls when possible:

  • RPS6KA1 knockdown (siRNA) or knockout (CRISPR) samples

  • The specific band should be significantly reduced or absent

• Consider band pattern and intensity:

  • Specific RPS6KA1 signal typically appears at 83-90 kDa

  • Non-specific bands often appear at inconsistent molecular weights or with different relative intensities across samples

• Perform peptide competition assays:

  • Pre-incubate antibody with blocking peptide (S-R-T-P-R sequence)

  • Specific bands should disappear while non-specific bands remain

• Optimize blocking conditions:

  • Use 5% BSA in TBST instead of milk for phospho-specific detection

  • Increase blocking time (2 hours) or concentration if background is high

• Cross-validation with other techniques:

  • Confirm results with immunoprecipitation or mass spectrometry

  • Use multiple antibodies targeting different epitopes

What could cause inconsistent RPS6KA1 antibody staining in immunofluorescence experiments?

Inconsistent immunofluorescence staining may result from:

• Fixation method incompatibility:

  • The RPS6KA1 (Ab-348) Antibody works best with methanol fixation

  • Paraformaldehyde may mask the epitope through cross-linking

• Permeabilization issues:

  • Insufficient permeabilization prevents antibody access to intracellular targets

  • Over-permeabilization may disrupt cellular architecture and epitope integrity

• Cell density and growth phase variations:

  • RPS6KA1 expression and localization changes based on cell density and cycle phase

  • Standardize cell plating density and growth conditions

• Antibody concentration optimization:

  • Too low: weak or no signal

  • Too high: high background and non-specific binding

  • Perform a dilution series (1:50 to 1:500) to determine optimal concentration

• Subcellular localization changes:

  • RPS6KA1 shuttles between cytoplasm and nucleus depending on activation state

  • Treatment with growth factors or stress may alter localization patterns

• Detection system sensitivity:

  • Match secondary antibody fluorophore to expression level (brighter fluorophores for lower expression)

  • Use appropriate exposure settings to avoid saturation or underdetection

How can RPS6KA1 (Ab-348) Antibody be utilized to investigate drug resistance mechanisms in cancer therapy?

Recent research has implicated RPS6KA1 as a mediator of resistance to venetoclax/azacitidine therapy in acute myeloid leukemia (AML) . Researchers can use RPS6KA1 (Ab-348) Antibody to:

• Monitor RPS6KA1 expression in resistant vs. sensitive cell populations:

  • Compare RPS6KA1 levels in parental and drug-resistant cell lines

  • Correlate expression levels with resistance phenotypes

• Evaluate RPS6KA1 inhibition as a therapeutic strategy:

  • Assess RPS6KA1 inhibition (e.g., with BI-D1870) via Western blot

  • Combined treatment with venetoclax/azacitidine decreased proliferation and colony-forming potential compared to venetoclax/azacitidine alone

• Identify cell subpopulations prone to therapy resistance:

  • Use immunofluorescence to detect RPS6KA1 expression in heterogeneous tumor samples

  • RPS6KA1 inhibition efficiently targeted monocytic blast subclones that may be sources of relapse

• Study downstream signaling mechanisms:

  • Investigate how RPS6KA1 activity affects apoptotic pathways using combination immunoblotting

  • Research indicates RPS6KA1 modulates mTOR signaling and represses pro-apoptotic functions of BAD and DAPK1

This approach can provide valuable insights for developing strategies to prevent or overcome drug resistance in AML and potentially other cancers.

How can I use RPS6KA1 (Ab-348) Antibody to investigate the differential activation of RPS6KA1 across cellular stresses and stimuli?

RPS6KA1 responds to various cellular stresses and stimuli. To investigate differential activation:

• Stimulus-specific activation profiling:

  • Treat cells with different stimuli (growth factors like EGF, PMA, stress inducers, etc.)

  • Use Western blotting with the RPS6KA1 (Ab-348) Antibody to detect total RPS6KA1

  • Pair with phospho-specific antibodies targeting key activation sites (T573, S380) to create an activation signature

• Temporal dynamics analysis:

  • Perform time-course experiments (5 minutes to 24 hours) after stimulation

  • Track RPS6KA1 expression, phosphorylation, and subcellular localization changes

  • Correlate with downstream target activation (e.g., CREB1, ETV1/ER81, NR4A1/NUR77)

• Subcellular localization studies:

  • Use immunofluorescence to track RPS6KA1 translocation between cytoplasm and nucleus

  • Co-stain with markers for specific organelles to identify precise localization

  • Different stimuli can induce distinct localization patterns

• Correlation with cellular outcomes:

  • Pair RPS6KA1 activation measurements with functional readouts (proliferation, survival, differentiation)

  • Identify stimulus-specific activation patterns that correlate with specific cellular outcomes

This approach provides insights into how RPS6KA1 integrates various external signals to coordinate appropriate cellular responses.

What are the methodological considerations for studying interactions between RPS6KA1 and the mTOR signaling pathway?

To investigate RPS6KA1 and mTOR pathway interactions:

• Co-immunoprecipitation studies:

  • Use RPS6KA1 (Ab-348) Antibody for immunoprecipitation (IP) at 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

  • Probe for mTOR pathway components (TSC2, RPTOR, DEPTOR)

  • RPS6KA1 directly phosphorylates TSC2 at Ser-1798, inhibiting its ability to suppress mTOR signaling

• Phosphorylation analysis of key substrates:

  • Examine phosphorylation status of:

    • TSC2 (Ser-1798)

    • RPTOR (regulatory subunit of mTORC1)

    • DEPTOR (feedback regulator of mTORC1/mTORC2)

  • Use phospho-specific antibodies in combination with RPS6KA1 manipulation

• Pharmacological perturbation:

  • Use mTOR inhibitors (rapamycin, torin1) alongside RPS6KA1 inhibition (BI-D1870)

  • Monitor effects on downstream targets using Western blot

  • RPS6KA1 promotes rapamycin-sensitive signaling independently of the PI3K/AKT pathway

• Functional readouts:

  • Measure protein synthesis rates using puromycin incorporation or 35S-methionine labeling

  • Monitor cap-dependent translation using reporter assays

  • RPS6KA1 regulates translation through RPS6 and EIF4B phosphorylation

• Analysis of translation initiation complex:

  • Examine RPS6KA1's impact on mRNA cap-binding complex formation

  • CK1-dependent phosphorylation of RPS6 promotes its association with the mRNA cap-binding complex in vitro

These approaches can elucidate the complex interplay between RPS6KA1 and mTOR signaling in cellular growth, proliferation, and survival.

How can RPS6KA1 (Ab-348) Antibody be used in multiplexed detection systems for comprehensive signaling pathway analysis?

For multiplexed detection systems:

• Sequential immunoblotting approach:

  • First probe with RPS6KA1 (Ab-348) Antibody

  • Strip and reprobe with antibodies against related pathway components

  • Create a comprehensive signaling profile including upstream activators (ERK1/2) and downstream targets

• Multi-color immunofluorescence:

  • Combine RPS6KA1 (Ab-348) Antibody with antibodies against other pathway components

  • Use species-specific or directly labeled secondary antibodies with distinct fluorophores

  • Analyze co-localization and correlation of expression/activation patterns

• Reverse phase protein array (RPPA) analysis:

  • Include RPS6KA1 (Ab-348) Antibody in antibody panels

  • Analyze hundreds of samples simultaneously for RPS6KA1 and related proteins

  • Ideal for large-scale studies of patient samples or drug screening

• Proximity ligation assay (PLA):

  • Combine RPS6KA1 (Ab-348) Antibody with antibodies against potential interaction partners

  • Detect protein-protein interactions with single-molecule resolution

  • Particularly useful for studying RPS6KA1 interactions with mTOR pathway components or translation machinery

• Mass cytometry (CyTOF):

  • Label RPS6KA1 (Ab-348) Antibody with rare earth metals

  • Combine with dozens of other antibodies for comprehensive signaling analysis

  • Enables single-cell analysis of RPS6KA1 in heterogeneous populations

These multiplexed approaches provide a systems-level view of RPS6KA1 function within complex signaling networks.

What is the significance of RPS6KA1 in the context of acute myeloid leukemia treatment resistance?

Research has revealed RPS6KA1 as a key mediator of resistance to venetoclax/azacitidine therapy in acute myeloid leukemia (AML):

• Identification through genome-wide screening:

  • A genome-wide CRISPR/Cas9 library screen targeting 18,053 protein-coding genes identified RPS6KA1 among the most significantly depleted sgRNA-genes in venetoclax/azacitidine-treated AML cells

• Experimental validation:

  • Addition of the RPS6KA1 inhibitor BI-D1870 to venetoclax/azacitidine decreased proliferation and colony-forming potential compared to venetoclax/azacitidine alone

  • BI-D1870 completely restored sensitivity in OCI-AML2 cells with acquired resistance to venetoclax/azacitidine

• Targeting specific cell subpopulations:

  • RPS6KA1 inhibition efficiently targeted monocytic blast subclones that are potential sources of relapse upon venetoclax/azacitidine treatment

  • This suggests heterogeneous expression or activation of RPS6KA1 within tumor populations

• Clinical implications:

  • RPS6KA1 inhibition represents a promising strategy to prevent or overcome resistance to venetoclax/azacitidine in AML patients

  • Monitoring RPS6KA1 expression levels may help predict treatment response

These findings highlight the potential of RPS6KA1 as both a biomarker and therapeutic target in AML treatment strategies.

How can researchers utilize the RPS6KA1 (Ab-348) Antibody to investigate cell type-specific functions of RPS6KA1?

To investigate cell type-specific functions:

• Comparative expression profiling:

  • Use the RPS6KA1 (Ab-348) Antibody for Western blot analysis across diverse cell types

  • Compare expression levels, phosphorylation states, and molecular weight patterns

  • Documented reactivity in various cell lines including HeLa, 3T3, and K-562 cells

• Single-cell analysis approaches:

  • Employ immunofluorescence to examine RPS6KA1 expression heterogeneity within tissues

  • Combine with cell type-specific markers to identify differential expression

  • Quantify intensity and subcellular localization on a cell-by-cell basis

• Tissue-specific knockdown/knockout studies:

  • Generate cell type-specific RPS6KA1 knockdown or knockout models

  • Use RPS6KA1 (Ab-348) Antibody to confirm knockdown efficiency

  • Compare phenotypic consequences across different cell types

• Context-dependent pathway analysis:

  • Investigate RPS6KA1 signaling networks in different cellular contexts

  • In fibroblasts: RPS6KA1 is required for EGF-stimulated phosphorylation of CREB1

  • In hepatic stellate cells: RPS6KA1 promotes survival by phosphorylating CEBPB

  • In hepatocytes: RPS6KA1 mediates induction of proliferation by TGFA through CEBPB phosphorylation

• Stimulus-dependent responses across cell types:

  • Compare how different cell types respond to the same stimulus via RPS6KA1

  • Identify cell type-specific substrates and downstream effects

This approach reveals how RPS6KA1 function is tailored to specific cellular contexts, providing insights into tissue-specific roles and potential therapeutic targeting strategies.

What are the optimal storage conditions for maintaining RPS6KA1 (Ab-348) Antibody activity?

To maintain antibody activity:

• Storage temperature:

  • Store antibody at -20°C for long-term preservation

  • Avoid repeated freeze-thaw cycles by preparing working aliquots

  • Stable for one year after shipment when properly stored

• Buffer composition:

  • Typical storage buffer: PBS with 0.02% sodium azide and 50% glycerol, pH 7.3

  • This formulation helps maintain antibody stability during freeze-thaw cycles

• Aliquoting recommendations:

  • Upon first thaw, prepare small working aliquots (10-20 μL)

  • Aliquoting is not necessary for -20°C storage, but prevents contamination and repeated freeze-thaw cycles

• Handling precautions:

  • Avoid contamination by using sterile technique

  • Minimize exposure to light, particularly for fluorophore-conjugated versions

  • Briefly centrifuge before opening to collect liquid at the bottom of the tube

• Working solution stability:

  • Diluted working solutions should be prepared fresh before use

  • If necessary, can be stored at 4°C for up to 1 week, but sensitivity may decrease

These storage recommendations ensure optimal performance and extend the shelf life of the antibody.

How should I troubleshoot weak or absent signal when using RPS6KA1 (Ab-348) Antibody?

If experiencing weak or absent signal:

• Sample preparation issues:

  • Ensure adequate protein extraction (verify total protein concentration)

  • Include phosphatase inhibitors in lysis buffer to preserve phosphorylation states

  • Confirm sample integrity (avoid protein degradation)

• Antibody-related factors:

  • Verify antibody concentration (try higher concentration, 1:200-1:500)

  • Check antibody storage conditions and expiration date

  • Consider using a positive control lysate (K-562 or HeLa cells)

• Protocol optimization:

  • For Western blot:

    • Increase primary antibody incubation time (overnight at 4°C)

    • Try more sensitive detection system (enhanced ECL)

    • Optimize transfer conditions for high molecular weight proteins

  • For immunofluorescence:

    • Try different fixation methods (methanol recommended)

    • Increase permeabilization time/concentration

    • Use signal amplification systems (tyramide signal amplification)

• Expression level considerations:

  • RPS6KA1 expression varies across cell types and conditions

  • Consider cellular treatments that enhance expression (growth factors, stress)

  • RPS6KA1 is activated downstream of ERK signaling

• Technical troubleshooting checklist:

  • Verify secondary antibody compatibility and activity

  • Check detection system function with a reliable control antibody

  • Ensure proper blocking to improve signal-to-noise ratio

These systematic approaches help identify and address the specific cause of weak signal issues.

How is RPS6KA1 research evolving in the context of cancer therapeutic resistance?

Recent developments in RPS6KA1 cancer research include:

• Identification as a resistance mediator:

  • Genome-wide CRISPR/Cas9 screens identified RPS6KA1 as a mediator of resistance to venetoclax/azacitidine in AML

  • This suggests RPS6KA1 may play a broader role in therapy resistance mechanisms

• Therapeutic targeting strategies:

  • RPS6KA1 inhibition with BI-D1870 restored sensitivity to venetoclax/azacitidine in resistant AML cells

  • Combinatorial approaches targeting RPS6KA1 alongside standard therapies show promise

• Subpopulation-specific effects:

  • RPS6KA1 inhibition efficiently targeted monocytic blast subclones that are potential sources of relapse

  • This highlights the importance of understanding tumor heterogeneity and subpopulation-specific dependencies

• Mechanistic insights:

  • RPS6KA1 modulates mTOR signaling and represses pro-apoptotic function of BAD and DAPK1

  • This provides a mechanistic link between RPS6KA1 activity and therapy resistance

• Translational potential:

  • RPS6KA1 inhibitors may represent a new class of agents to overcome resistance

  • Expression levels could serve as biomarkers to predict treatment response

Researchers can use RPS6KA1 (Ab-348) Antibody to further explore these aspects, potentially leading to new therapeutic strategies for overcoming resistance in various cancer types.

What are the emerging techniques for studying RPS6KA1 phosphorylation dynamics in live cells?

Cutting-edge approaches for studying RPS6KA1 phosphorylation dynamics include:

• FRET-based biosensors:

  • Design biosensors that undergo conformational changes upon RPS6KA1 phosphorylation

  • Monitor real-time activation dynamics in living cells

  • Correlate with cellular responses to stimuli

• Optogenetic activation systems:

  • Develop light-inducible RPS6KA1 activation systems

  • Control RPS6KA1 activity with precise spatial and temporal resolution

  • Combine with the RPS6KA1 (Ab-348) Antibody for validation in fixed cells

• Live-cell phospho-specific antibody fragments:

  • Generate cell-permeable antibody fragments derived from RPS6KA1 (Ab-348) Antibody

  • Label with fluorescent dyes for real-time imaging

  • Monitor endogenous RPS6KA1 phosphorylation states

• Mass spectrometry-based phosphoproteomics:

  • Use targeted mass spectrometry to quantify multiple RPS6KA1 phosphorylation sites

  • Perform time-course experiments to map phosphorylation dynamics

  • Validate findings using RPS6KA1 (Ab-348) Antibody in conventional assays

• Nanobody-based detection systems:

  • Develop nanobodies against specific RPS6KA1 epitopes and phosphorylation sites

  • Express as intracellular probes fused to fluorescent proteins

  • Track RPS6KA1 activation in real-time

These emerging techniques, complemented by validation with traditional RPS6KA1 (Ab-348) Antibody-based approaches, promise to provide unprecedented insights into the spatiotemporal dynamics of RPS6KA1 activation in cellular processes.